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Abstract
Up to now eight patients with a-NAGA 
deficiency have been described. This in­
cludes the newly identified patient re­
ported here who died unexpectedly aged 
l |  years of hypoxia during convulsions; 
necropsy was not performed.
Three patients have been genotyped pre­
viously and here we report the mutations 
in the other five patients«, including two 
new mutations (S160C and E193X). The 
newly identified patient is consanguineous 
with the first patients reported with a- 
NAGA deficiency and neuroaxonal dys­
trophy and they all had the a-NAGA geno­
type E325K/E325K.
Clinical heterogeneity among patients 
with a-NAGA deficiency is extreme* Two 
affected sibs, homozygotes for E325K, are 
severely affected and have the signs and 
symptoms of infantile neuroaxonal dys­
trophy, but prominent vacuolisation is 
lacking« The mildly affected patients (two 
families, three patients) at the opposite 
end of the clinical spectrum have clear 
vacuolisation and angiokeratoma but no 
overt neurological manifestations. Two of 
them are homozygous for the stop muta­
tion E193X, leading to complete loss of 
a-NAGA protein. These observations are 
difficult to reconcile with a simple geno- 
type-phenotype correlation and we sug­
gest that factors or genes other than a- 
NAGA contribute to the clinical hetero­
geneity of the eight patients with a-NAGA 
deficiency.
At the metabolic level, the patients with 
a-NAGA deficiency are similar. The major 
abnormal urinary oligosaccharides are si- 
alylgly copeptides of the O linked type. Our 
enzymatic studies indicated that these 
compounds are not the primary lysosomal 
storage products.
(J M e d  Genet 1996;33:458-464)
Key words: a-N-acetylgalactosaminidase; a-N A G A  de­
ficiency; processing.
In 1987 two German infants were reported by 
Van Diggelen et aV with a profound deficiency 
of the lysosomal enzyme a-N-acetylgalactos­
aminidase (a-NAGA). Schindler et aP reported 
that the patients had infantile neuroaxonal dys­
trophy without visceral involvement or dys- 
morphism. Two years later Kanzaki et aP~5
reported the second independent case of a- 
NAGA deficiency with an entirely different 
clinical phenotype. This patient had a late onset 
disease with slight facial coarseness, dis­
seminated angiokeratoma, and mild intellectual 
impairment (IQ —70), but without neuro­
logical symptoms. Unlike the infantile cases, 
this patient had prominent vacuolisation in all 
dermal cells, most prominently in vascular and 
lymphatic endothelial cells and eccrine sweat 
gland cells, but also in dermal neural cells and 
fibroblasts.5 The glomerular endothelial cells 
but not the epithelial kidney cells are involved 
and also blood lymphocytes are vacuolised.6
These three patients shared, however, the 
abnormal urinary excretion of specific oli­
gosaccharides. The major compounds are si- 
alylglycopeptides of the O-glycosidic type with 
serine or threonine linked to the a-N-acet- 
ylgalactosamine (aGalNAc) moieties.78 Using 
an aGalNAc specific lectin, intralysosomal 
storage products were shown in lysosomes of 
cultured fibroblasts from the infantile patients.9
The a-NAGA gene codes for 411 amino 
acids10 and consists of nine exons.11 Mutation 
analysis of the a-NAGA gene showed the 
mis sense mutation E325K in the infantile 
cases1*; both patients were homozygous for 
this mutation. The adult patient was found 
to be homozygous for the missense mutation
R329W.14
Recently, four additional patients with a- 
NAGA deficiency were reported in two in­
dependent families. The index case in the 
Dutch family, reported by de Jong et al315 had 
psychomotor retardation at the age of 4 years. 
Screening her sibs showed that a healthy sib with 
a-NAGA deficiency has no overt clinical symp­
toms at the age of 3 years. Chabas et a t6 reported 
adult patients of Spanish origin with a mild 
phenotype consisting of angiokeratoma, slight 
dysmorphism, lymphoedema, and prominent 
vacuolisation in endothelial cells, resembling 
the case reported by Kanzaki et al? In this paper 
we report the mutations of these four patients 
and describe a new German case with infantile a- 
NAGA deficiency. The genotype and phenotype 
of the presently known eight cases of a-NAGA 
deficiency are discussed.
Patients and methods
CASE REPORTS
The two German brothers, first reported by van 
elen et aP and Schindler et aP with a severe 
infantile form of a-NAGA deficiency, are
•i
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Table 1 Oligonucleotide primers used to sequence and PCR amplify the coding regions o f  
the a -N A G A  gene
Exon* Primer sequences'  ^ and (location in gene*)
Length of fragment sequenced 
and (relative position to exon%)
1
8
s: GCCTAAGGTTGAGGGCGG (1646-1663) 
as: GAAGGGCCAAAGCACTCCTT (1854-1873) 
s: AGCTGTGGGGGCAACTGATA (3479-3498) 
as: GGCAAGGCTCATCAGGTGA (3683-3701) 
s: GAGGCAGGGTGTGGGTGA (4101-4118) 
as: GCCCTAAGCGAGGTAGGGTG (4389-4408) 
s: GTCCTGCTTGAGCCCACTGT (4777-4796) 
as: CCCTCCCCGTTTGCCTAC (5019-5036) 
s: CCAGACTGCCTCCTGCACTT (5244-5263) 
as: AGGTAAGGAGGCCTGGGTGT (5428-5447) 
s; CTGGTGCTGGACTCTGCCTT (6157-6176) 
as: GCAGGGTCGTCACAGATGG (6386-6404) 
s: CCTCCTTGAGGAGATGAGAGC (8991-9011) 
as: CTCAGCCCTCCCCTTCCTT (9254-9272) 
s: AGATAAGCTGGGGTGCTGGA (10832-10851) 
as: CCCACAGAAATCTGAAGCCC (11163-11182) 
s: CTGTGCCCCACTCTCATGG (11587-11605) 
as: AGGCTCAGTGGTGCCACC (11795-11812)
228 bp ( — 60§ to +31) 
223 bp ( -1 1  to +2) 
308 bp ( - 2 9  to +32) 
260 bp ( - 1 7  to +23) 
204 bp ( - 2 2  to +29) 
248 bp ( — 7 to + 18) 
282 bp ( — 4 to +13) 
351 bp ( - 6 4  to +5) 
226 bp ( - 1 2  to +911)
* Exon number and position of nucleotide in a-NAGA gene according to accession No M59199. 
f s  = sense strand; as = antisense, All primers shown in 5' to 3' direction.
Î  Relative position to exon; — = upstream and + ^downstream of exon.
§ Position upstream of start codon in exon 1.
11 Position downstream of stop codon in exon 9,
Table 2 The mutations in all patients with a -N A G A  deficiency
Patient Nucleotide change* (exon!exon) Protein change* Reference
D l.l G11005A (8/8) E325K7E325IC 13
D1.2 G11005A (8/8) E325K/E325K 13
D2.1 G11005A (8/8) E325K/E325K Present paper
NL1.1 C4969G/G11005A (4/8) S160C/E325K Present paper
NL1.2 C4969G/G11005A (4/8) S160C/E325IC Present paper
J l . l C11017T (8/8) R329W/R329W 14
E l.l G5371T (5/5) E193X/E193X Present paper
E l,2 G5371T (5/5) E193X/E193X Present paper
* Nucleotide and amino acid numbering is according to Yamauchi et als(l and accession No 
M59199.
The exons in which the mutation was found are shown in brackets.
designated D l.l  and D1.2. The patients have 
remained in a vegetative state for the last few 
years and are at present 12 and 11 years of age.
The newly diagnosed German patient D2.1 
lived in the same village as the D 1 family and 
is consanguineous with the German patients in 
family D l. The pregnancy and development 
up to die age of 6 months were normal. From 
7 months, the patient had several convulsions, 
most of them during fever caused by upper 
respiratory tract infections. He died at the age 
of 18 months of hypoxia during a prolonged 
convulsion causing apnoea. During the last 3 
months of his life, his development seemed to 
have stopped. He had never been admitted to 
a hospital and necropsy was not performed.
The two Dutch patients reported by de Jong 
etal15 are designatedNL1.1 andNL1.2. Patient 
NL1.1 was last seen at the age of 3-8 years and 
was retarded. After the age of 2*4 years she 
had four convulsions, mostly associated with 
fever, despite treatment with antiepilectic 
drugs. In retrospect, the retardation began after 
a severe episode around the age of 1 year. 
The patient had a high fever, uncontrollable 
convulsions, and attacks of apnoea and brady­
cardia which required admission to the intens­
ive care unit. The fever and convulsions 
responded to medication, but a few days after 
detubation she developed pneumonia with high 
fever and the clinical signs of sepsis with mul­
tiple organ failure, from which she recovered 
slowly without convulsions. Her brother 
(NL1.2) appeared healthy at the age of 3 years
on visual examination, but neurological tests 
have not been performed.
The Spanish patients reported by Chabas et 
ai]() are designated E l . l  and E l .2.
CELL CULTURE AND ENZYME ASSAYS
Skin fibroblasts were cultured according to 
routine procedures in Ham's F10 medium sup­
plemented with 10% fetal bovine serum and 
antibiotics. The cells were harvested widi tryp­
sin seven days after the last subculture and 
were stored at — 70°C until use.
a-N-acetylgalactosaminidase (aNAGA) ac­
tivity was assayed in homogenates prepared 
by sonication of cultured fibroblasts in water. 
Reaction mixtures consisted of 10 f.i\ homo- 
genate (30 ¡.ig protein for patient materials or 
5 fig for controls) and 20 ¿¿1 1 mmol/1 MU- 
aGalNAc, Moscerdam Substrates, Rotterdam) 
in Mcllvain’s phosphate/citrate buffer, pH 4.7. 
After incubation for one hour at 37°C, the 
reactions were terminated by the addition of 
200 /d 0*5 mol/1 N a2G 0 3/N aH C 0 3, pH 10.7, 
and the fluorescence of 4-methylumbelliferone 
(MU) was measured wjth a Fluoroskan (Titer- 
tek) fluorimeter. /j-gal act os idase activity, using 
an MU substrate, and protein content of cell 
homogenates was determined as described pre­
viously.17 /?-galactosidase was also determined 
with the disaccharide Gal/?1 — 3GalNAc 
(Oxford GlycoSystems) in a galactose de­
hydrogenase based assay.1” Reaction mixtures 
(30 /d) contained 20 ¿ig protein from sonicated 
fibroblast homogenates, 2-7 mmol/1 of the dis­
accharide, 67 mmol/1 NaCl in 67 mmol/1 so­
dium acetate buffer, pH  4*3, and were 
incubated for three hours at 37°C, after which 
200/d 0*1 mol/1 Tris/HCl, pH 8-6 containing 
0-6 mmol/1 N A D + and 0 T 3 U  galactose de­
hydrogenase (Boehringer) was added. Free ga­
lactose was then determined by measuring the 
absorbance at 340 nm, after incubation for 25 
minutes at room temperature.
Neuraminidase activity was determined by 
the standard mediod using the MU substrate19 
as well as with a disialyltetraose substrate (DST, 
NeuAca2-~3Gal/?l-3 [NeuAca2 — 6]GalNAc, 
Oxford GlycoSystems). Reaction mixtures 
(30 /d) contained 50 /¿g protein from fibroblast 
homogenates (Potter homogenised), 1*3 mmol/1 
DST, 67 mmol/1 NaCl in 67 mmol/1 sodium 
acetate buffer, pH 4-3, and were incubated for 
three hours at 37° C. Then free N-acetyl- 
neuraminic acid (NANA) was purified as pre­
viously described20 and determined with the 
thiobarbituric acid method as described by 
Denny et al.2I
IM M UNOBLOTTING
The polyclonal antibody against human a- 
NAGA, raised in rabbits, was used at a 1000 
fold dilution and immunoblotting was per­
formed as previously described.12
LABELLING OF G£-GALNAC M OIETIES BY 
LECTIN HISTOCHEM ISTRY
The lectin from Helix pomatia (Sigma), which 
is specific for aGalNAc, was used to stain
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Figure 1 Restriction enzyme analysis of PCR amplified a-N AG A exons 8 and 4. Top 
panel: Bsgl digests of exon 4 of N L I  patientsy their parents3 and a healthy sib. Bottom 
panel: TaqI digests of exon 8 of the N L  J patients, their parents} and patient D 2 .1.
Control
Mse I 
Exon 5
E1*1 E1-2
-  204
-  127
-  77
Figure 2 Restriction enzyme analysis of PCR amplified y-N A G A  exon 5, M sel digests 
of exon 5 of E l  patients and their parents.
aGalNAc containing material in cultured 
fibroblasts as described.9
METABOLIC LABELLING
Cultured fibroblasts were labelled with 35S- 
methionine following the procedure described 
earlier.12
DNA AM PLIFICATION AND SEQUENCING
DNA was isolated from cultured fibroblasts by 
standard procedures.22 PCR amplification and
sequencing was performed according to Her­
mans et al.23 Restriction enzyme digestions 
(:TaqI, Boehringer; Zfygl and Msel, BioLabs) 
were performed according to the man­
ufacturers’ instructions.
Results
THE GENOTYPE OF Oi-NAGA DEFICIENCY
Using die intron primer sets shown in table 13 
DNA fragments encompassing the entire open 
reading frame of the nine exons of the a-NAGA 
gene were amplified and sequenced (except for 
patient D2.1); this included all flanking intron 
regions (table 1).
Since patient D2.1 is consanguineous with 
the D1 patients^ only exon 8 was analysed^ 
and the presence of the G11005A mutation 
(E325K) was confirmed (table 2). This muta­
tion destroys a TaqI restriction site and its 
presence could be confirmed by TaqI digestion 
of the 351 bp long PCR products of exon 8. 
The digestion of the normal PCR product into 
fragments of 174 and 177 bp was not observed 
in the PCR products of the mutant alleles (fig 
1). Sequence analysis of the sense and antisense 
strand as well as restriction enzyme analysis 
showed that patient D2.1 is homozygous for 
the E325K mutation (fig 1). We obtained the 
same results for the D1 patients (data not 
shown).
Sequence analysis of all a-NAGA exons of 
die Dutch sibs (NL1) showed two different 
mutations. The C11017G substitution in exon 
4 (S160C) could be confirmed with the re­
striction enzyme Bsgl (die mutation creates a 
new restriction site). Fig 1 shows that the affec­
ted sibs are heterozygous for this mutation 
which is of maternal origin. The paternal muta­
tion in these sibs is the previously described 
E325K mutation of die German patients. The 
father of the Dutch patients is not of German 
ancestry. The healthy sib of the NL1 patients 
showed the normal pattern in both exons 4 and 
83 indicating that she is not a carrier of eitiier 
mutation (fig 1). The S160C mutation was not 
detected in 80 Dutch white control alleles.
Sequence analysis showed that both Spanish 
(El) patients were homozygous for the non­
sense mutation E193X. Homozygosity was 
confirmed using the restriction enzyme Ai^I 
(die mutation creates a new restriction site). 
In agreement with this observation, bodi par­
ents of the E l sibs showed a heterozygous 
pattern after Msel digestion of their PCR prod­
uct of exon 5 (fig 2).
The entire sequenced parts of the a-NAGA 
gene (table 1) were identical in all patients 
and two controls (with the exception of the 
mutations). Differences, however, were found 
with the published sequence of the a-NAGA 
gene (Wang and Desnick, accession No 
M59199). In intron 1, starting at position 3516, 
we detected CCCTTGCCCCC (discrepancies 
underlined, three Gs in sequence M59199). In 
exon 3 we detected three polymorphisms (no 
amino acid changes) in all samples analysed, 
which had previously been published by Ya- 
mauchi et aL10 In all the DNA samples we 
tested, a C was found at position 4239 instead
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Table 3 a-NA GA activity in fibroblasts from patients 
with infantile and adult a-NA GA deficiency
a -NAGA activity 
(nmolihimg)
Infantile cases
D l . l 0-5
D1.2 1-0
D2.1 1-4
NL1.1 3*2
Adult patients
E l . l 0-2
E l.2 0-2
Control range
Range n =  34 40-130
(mean) (81)
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of an A and at position 4263 there was a T  
instead of a C. In both alleles of the two controls 
and in one allele of the NL1 patients^ an A-»G 
substitution at position 4293 was found. In 
intron 33 starting at position 4348 we found 
four Cs instead of three Cs and starting at 
position 4364 we found GGCC instead of 
GCGC. In intron 5, at position 5404 we found 
aC -^G  substitution.
THE BIOCHEMICAL PHENOTYPE OF 
CHSIAGA DEFICIENCY
We studied the effect of these point mutations 
on the steady state level of a-NAGA activity 
and observed differences among the various 
patients. The highest activity was measured in 
fibroblasts of patient NL1.1. About half this 
activity was present in cells from the D2.1 and 
D1 patients* whereas a-NAGA activity in the 
E l patients was barely detectable (table 3).
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Figure 3 Immunoblot of a-NAGA from patients with C/.-NAGA deficiency. Fibwblast 
homogenates (150 fig protein) were used. For patient codes see Patients and methods 
section.
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Figure 4 Pulse chase labelling o f  a-NA GA in fibroblasts 
from patients with a-NA GA deficiency. Cells were labelled 
with S-methionine for four hour (pulse) > or they were 
labelled for four hours and subsequently maintained for 17 
hours in label free medium. a-N A GA was then 
irnmunoprecipitated and analysed by SDS-PAGE. 
Molecular weight markers are shown on the right hand 
side in kD a .
These low residual activities and their differ­
ences are genuine since the activities are linear 
with the amount of protein and incubation time 
and reproducible (data not shown). Using a 
polyclonal antibody against a-NAGA* we 
showed that in all cases the deficiency of a- 
NAGA enzyme activity was associated with 
undetectable levels of a-NAGA protein (fig 3). 
Metabolic labelling of cultured fibroblasts for 
four hours, followed by immunoprécipitation 
of native a-NAGA protein showed that the 
synthesis of precursor a-NAGA (50 kDa) is 
normal in the NL1 patients and patient D1.2 
(fig 4). The E l patients* on the other hand* do 
not synthesise any a-NAGA protein. Mat­
uration of newly synthesised a-NAGA was in­
vestigated after a 17 hour chase period and 
mature enzyme (45 kDa) was not detectable in 
the German patient DL2* whereas a small 
amount was present in the NL1 patients 
(fig 4).
At die cellular level* a-NAGA deficiency was 
reflected in the lysosomal storage of aGalNAc 
containing compounds (fig 5)* which were 
identified with the aGalNAc specific lectin 
from Hpomatia. On the other hand all patients 
with a-NAGA deficiency excrete sialylglyco- 
peptides* the new patient D2.1 included (data 
not shown). Unlike the unknown structure of 
the intralysosomal storage products* the ab­
normal urinary excretion products have been 
fully characterised. We have investigated 
whether fibroblast homogenates of the most 
severe patient with a-NAGA deficiency (D1.2) 
can hydrolyse the core structures of these 
urinary compounds: NeuAca2 — 3Gal/il — 3 
[NeuAca2 — 6] GalNAc and Gal/51 — 3GalNAc. 
The results show that fibroblasts with a-NAGA 
deficiency are fully normal in their sialidase 
and /5-galactosidase activity towards these oli­
gosaccharides (table 4).
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Figure 5 Intracellular labelling of v-N-acetylgalactosamine containing compounds in 
fibroblasts from patients with a-NA GA deficiency. Lectin histochemistry^ using the 
aGalNAc specific lectin from Helix pomatia* was carried out on cultured fibroblasts from 
a control (A)j the patients D L 2  ("B) , D2.1 (C )3 N L L 1  (D), E L I  (E) 3 and E l .2 (F).
Table 4 Degradation o f core structures of O-glycosidic glycoproteins by neuraminidase 
and fi-galactosidase
Neuraminidase activity* Ji-gaIactosidase activity*
M U-NANA-t DST% MU-fîGa® G aïfiJ-3 GalNAc
a-NAGA deficiency (D1.2) 78 28 750 650
Control 45 18 560 480
GM1-gangliosidosis 35 13 2 Not detectable
Sialidosis 0.3 1 430 450
* Enzyme activities; nmol/h/mg, 
f  4-methylumbelliferyl-K-D-N-acetylneuraminic acid. 
:j:DST~disialyltetraose: NeuAc«2 —3Gal/il — 3[NeuAca2 — 6]GalNAc. 
§ 4-methylumbelliferyI-/ï-D-galactoside.
Discussion
Deficiency of a-N-acetylgalactosaminidase (a- 
NAGA) would imply major urinary excretion 
products containing terminal aGalNAc res­
idues at the non-reducing end; however* this 
is not observed. All patients with a-NAGA 
deficiency excrete sialylglycopeptides with ter­
minal neuraminic acid and the a-GalNAc moi­
ety is internal* a linked to serine or threonine.78 
The structures are identical to those present 
in O linked glycoproteins. Using their core 
structure (NeuAc<x2 — 3Galfil —3 [NeuAca2 — 6] 
GalNAc and Gal/?1 — 3GalNAc) we showed 
that fibroblasts from the severe D1.2 patient 
(table 5) can hydrolyse sialic acid and galactose 
from these compounds. This indicates that 
the sialylglycopeptides from urine are not the 
primary lysosomal storage products, which 
will probably be GalNAcal — Ser/Thr. Minor 
amounts of these compounds have been de-
tected in urine of the D1 patients.24 These 
putative primary storage products could sub­
sequently serve as acceptor for the synthesis of 
the O linked type oligosaccharides. Addition 
of glycosides to primary lysosomal storage 
products (resynthesis) has been reported for 
aspartylglucosaminuria2526 and /i-mannosid- 
osis.27 Although we have shown an aGalNAc 
containing lysosomal storage product in fibro­
blasts of all patients (we did not have per­
mission to investigate fibroblasts from the 
Japanese patient), the structure of these com­
pounds is still unknown. Studies are in progress 
to identify these primary lysosomal storage 
products.
a-NAGA deficiency is one of the rarest and 
probably most heterogeneous lysosomal stor­
age disorders. At present* only eight patients 
are known from five families of German (D), 
Japanese (J)* Dutch (NL): and Spanish (E) 
descent, including the new case reported here 
(table 5). Clinical variability is common in 
lysosomal storage disorders but overlapping 
signs and symptoms of subtypes is the rule. 
In a-NAGA deficiency, however, infantile and 
adult patients have no obvious overlap of signs 
and symptoms. This led us to consider the 
possibility that the phenotype of the eight 
patients is not solely determined by the a- 
NAGA deficiency. Three observations are 
difficult to reconcile with a simple genotype- 
phenotype correlation.
(1) At the histological level, prominent 
vacuolisation* the hallmark of lysosomal storage 
disorders, was observed in dermal endothelial 
cells of the late onset patients (patient J l . l ,35 
patients of the E l family16) but was not ob­
served in the severely affected patients of the 
D1 family.2 This is remarkable since vacuo- 
lisation is usually prominent in the most severe 
subtype of lysosomal storage disorders and less 
evident* or even absent, in the milder sub- 
types.28 The most striking histopathology in the 
infantile patients (Dl) is non-lysosomal, the 
presence of “spheroids” in axons. Although 
axonal spheroid formation has been observed 
in other lysosomal storage disorders,2930 it is a 
peculiar phenomenon in the absence of clear 
lysosomal histopathology and difficult to ex- 
plain.
(2) Enzyme activity is often undetectable in 
the most severe subtype of a lysosomal disorder 
whereas patients with milder subtypes have 
residual activity. This has conclusively been 
shown for metachromatic leucodystrophy and 
Tay-Sachs disease31 and for Pompe’s disease.32 
Such a logical correlation is missing in a-NAGA 
deficiency. We found a stop mutation (E193X), 
deleting half the protein* in the mildly affected 
Spanish patients (El). A translation product 
could not be detected by immunoblotting, 
metabolic labelling of newly synthesised a- 
NAGA did not indicate the presence of a trun­
cated protein, and enzyme activity was virtually 
zero. This indicates tiiat these patients have, 
in essence* null alleles and one would expect 
the most severe phenotype. In contrast, these 
patients presented with a mild, late onset dis­
ease, whereas the most severely affected 
patients (Dl) have significant, albeit very low,
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Infantile a-NAGA deficiency Adult a-NA G A deficiency
D1.1* DL2* D2. I f NL1.1% NL1.2% JL  /§ EL 1\\ El. 2\\
Age
Age at onset i y 6 mth 7 mth iy No symptoms? 28 y 14 y m
Present age (age at death) 13y 12y (l*5y) 5 y 3*6y 51 y 42 y 38 y
Neurological signs
Convulsions during fever H- + — — — —
Epilepsy “K + + + + + + — -— — —
Psychomotor retardation + + + + -{- -f 7< + ?« — — —
Hypotonia +  + + + -l~ + ?• ■—■ — — —
Physical signs
Skeletal abnormalities — — — — — <— —
Dysmorphism — — --------------- , — — i i ?4
Organomegaly — — -------------- — — — - —
Angiokeratoma — — -------------- — — + + + + + +
Lymphoedema — — -------------- — — — 4" H—h P  ^
Histology
Vacuolisation — N il — — + + + + + +
Neuroaxonal dystrophy + + + N il — — — — —
a-GalNAc lectin staining + + + + + + NA** NA** H— h ~\r + +  +
Mutations Homozygous E325K S160C/E325K Homozygous R 329W tt Homozygous E193X
*D1: van Diggelen et a!,' Schindler et a l2 
fD 2.1: present paper.
|N L l :  de Jong et al}5 
§ J l . 1: Kansalci et al,3 
if El: Chabas et. al,u>
*l|NI =  not investigated.
**NA — material not available, 
f t  Wang et al.1*
residual enzyme activity. A logical correlation 
was similarly lacking in studies of Wang et aln 
comparing the severe German patients (Dl) 
and the Japanese patient J l . l  with adult a- 
NAGA deficiency.14 The authors could not 
detect significant a-NAGA enzyme activity in 
either case.
(3) After the clinical description of the first 
patients with a-NAGA deficiency (D l), many 
laboratories* including ours, have screened Se- 
itelberger patients (infantile neuroaxonal dys­
trophy) for a-NAGA deficiency, blit a second 
patient with combined a-NAGA deficiency and 
neuroaxonal dystrophy has not been found.
These three observations indicate that factors 
other than a-NAGA contribute to the pheno­
typic variation of the patients. The simplest 
explanation would be that the severe infantile 
patients (Dl) have a “double disease”, ne­
uroaxonal dystrophy in addition to a-NAGA 
deficiency, without a causal relationship. Ac­
cidental occurrence of two independent mono­
genic diseases in one patient can be observed., 
particularly in consanguineous families (the 
parents of the patients D l.l  and D1.2 are 
consanguineous). For example, in one of the 
contributing laboratories (Rotterdam) four 
cases are known: glycogenosis II combined with 
methylmalonic aciduria, neurofibromatosis I 
with multiple sulphatase deficiency, Niemann- 
Pick type C with Hurler disease, and combined 
Zellweger syndrome and sulphite oxidase de­
ficiency. One of the first patients with /?~man~ 
nosidosis33 had mucopolysaccharidosis type III 
A as a second disease.3334
If the severely affected German patients (Dl) 
did have a double disease, this phenotype is 
not representative of “true” a-NAGA de­
ficiency. The phenotype associated with com­
plete a-NAGA deficiency would be a mild, late 
onset disease with angiokeratoma manifested 
in patient J l . l  and the Spanish patients (El). 
The Dutch patient NL1.2, aged 3*3 years with­
out overt signs or symptoms, could be a pre- 
clinical case of a-NAGA deficiency detected
through screening. The newly identified mis- 
sense mutation in the Dutch patients (S160C) 
results in 4% residual activity, the highest level 
among all the patients with a-NAGA de­
ficiency; this may contribute to the mild pheno­
type. Only in these patients a small amount of 
mature a-NAGA protein was found 17 hours 
after metabolic labelling of the enzyme in cul­
tured fibroblasts, which is in agreement with 
the significant residual enzyme activity. The 
newly identified patient D2.1, who had ident­
ical a-NAGA mutations as the patients with 
neuroaxonal dystrophy (D l), could in time 
have provided important information as to the 
relation of a-NAGA deficiency and neuro­
axonal dystrophy, but the patient died at the 
age of 1~ years of hypoxia during a convulsion 
without being examined histologically and 
neurologically.
In summary, all the genetic, biochemical, 
histological, and clinical data of all patients with 
a-NAGA deficiency strongly suggest that a- 
NAGA deficiency is not a single disease eijtity. 
The possibility that factors other than a-NAGA 
play a major role in determining the phenotypic 
variation of the eight known patients with a- 
NAGA deficiency deserves serious con­
sideration. The future discovery of new patients 
with a-NAGA deficiency will eventually estab­
lish which phenotypes are solely caused by a- 
NAGA deficiency and if other factors/genes play 
a role in other phenotypes. This will probably 
take a long time since the discovery of the first 
eight p atients took almost a decade. It will there­
fore pay to study the association of a-NAGA 
deficiency and neuroaxonal dystrophy in an a- 
NAGA knock-out mouse.
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